MannKind
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine ...
Latest News
5 days ago · seekingalpha.com
MannKind's ReadyFlow Launch Keeps The Bull Case AliveMNKD's ReadyFlow could widen Furoscix's reach into more outpatient settings, which I consider a promising value driver in the long run. Also, their pediatric launch expands Afrezza's market. The main caveat to this is that it requires an added lung-function screening for patients. Aside from that, Tyvaso DPI royalties remain vital for MNKD, but fortunately, they're likely to keep growing as well in the near term.
11 days ago · seekingalpha.com
MannKind Corporation (MNKD) Q3 2026 Earnings Call TranscriptMannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
11 days ago · marketbeat.com
MannKind Q3 Earnings Call HighlightsMannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza launches gain traction.
11 days ago · zacks.com
Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key MetricsAlthough the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
11 days ago · zacks.com
MannKind (MNKD) Reports Q3 Loss, Misses Revenue EstimatesMannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.
18 days ago · globenewswire.com
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.
1 month ago · globenewswire.com
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across injection sites support flexible administration in clinical practice Cross-study analysis demonstrates comparable diuretic and natriuretic responses between Furoscix ReadyFlow and Furoscix (furosemide) On-body Infusor, supporting a seamless transition to ReadyFlow Data presentations build on the July 2026 FDA approval and U.
2 months ago · marketbeat.com
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains MomentumMannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.
2 months ago · globenewswire.com
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight ManagementCollaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
3 months ago · globenewswire.com
MannKind to Present at Upcoming Investor ConferencesDANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MNKD